Activating β-catenin (Ctnnb1) mutations have previously been implicated in progression to carcinoma, but in a two-stage model where DEN is given as the initiator followed by treatment with phenobarbital as a tumour promoter.14 Here, CTNNB1 is linked to carcinoma.